INO Pharmaceuticals is a potential COVID-19 winner
Inovio Pharmaceuticals (INO) currently trades at $8.24 and has fallen by 0.60% today. INO shares are up by 153% since the beginning of the year. In February, Inovio claimed it had developed a potential vaccine for COVID-19 in three hours after the genetic sequence for the SARS-CoV-2 virus that causes the disease was made public by Chinese researchers on Jan. 10.
Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article. The high forecast for Inovio Pharmaceuticals is $13.00 and the low is $7.00. Notably, the company’s market cap is $1.20 billion with a 52 week high of $19.36 and a 52 week low of $1.92. INO went down $0.04 from the previous closing price of $8.19. INO has changed in price by 4.29 per share in the last 12 months.
Inovio’s technology platform is capable of activating antigen-specific immune responses. With demonstrated efficacy in a Phase 2b trial, robust and targeted immune responses, a favorable safety profile, and a robust pipeline of product candidates across multiple disease states, the evidence to date is clear—Inovio is realizing the true promise of immunotherapy.